{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:05:02Z","timestamp":1787929502975,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI106850"],"award-info":[{"award-number":["AI106850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI054384"],"award-info":[{"award-number":["AI054384"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI070218"],"award-info":[{"award-number":["AI070218"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bmc.2016.11.019","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T11:17:38Z","timestamp":1478949458000},"page":"1571-1584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors"],"prefix":"10.1016","volume":"25","author":[{"given":"Andriy","family":"Buchynskyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Robert","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Hulverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Creason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranae M.","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Duster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Gelb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2016.11.019_b0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, noninferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2016.11.019_b0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/510534","article-title":"Equivalence trial of Melarsoprol and Nifurtimox monotherapy and combination therapy for the treatment of Second-Stage Trypanosoma brucei gambiense Sleeping Sickness","volume":"195","author":"Bisser","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2016.11.019_b0015","unstructured":"New Oral Drug Candidate for African Sleeping Sickness; DNDi press release [Geneva, Switzerland and Kinshasa, Democratic Republic of the Congo \u2013 6 December 2012]. http:\/\/www.dndi.org\/media-centre\/press-releases\/354-media-centre\/pressreleases\/1505-new-oral-drug-candidate-hat.html."},{"key":"10.1016\/j.bmc.2016.11.019_b0020","unstructured":"Pivotal Clinical Trial to Begin for First Oral Drug Candidate Specifically Developed for Sleeping Sickness; DNDi press release [Basel, Switzerland \u2013 8 September 2015]. http:\/\/www.dndi.org\/2015\/media-centre\/press-releases\/pr-scyx-7158\/."},{"key":"10.1016\/j.bmc.2016.11.019_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2016.11.019_b0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2016.11.019_b0035","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery for Leishmaniasis and Human African Trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2016.11.019_b0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2016.11.019_b0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2016.11.019_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.bmc.2016.11.019_b0055","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/jm401178t","article-title":"Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis","volume":"57","author":"Tatipaka","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0060","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1021\/jm500191u","article-title":"Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei","volume":"57","author":"Ferrins","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0065","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acs.jmedchem.5b00438","article-title":"6-Arylpyrazine-2-carboxamides: a new core for Trypanosoma brucei inhibitors","volume":"58","author":"Rahmani","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0070","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1016\/j.bmcl.2013.05.049","article-title":"Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei","volume":"23","author":"Hwang","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2016.11.019_b0075","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1021\/jm301687p","article-title":"Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for Human African Trypanosomiasis (HAT)","volume":"56","author":"Hwang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0080","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.01796-10","article-title":"Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei infection in mice","volume":"55","author":"Shibata","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2016.11.019_b0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro","volume":"68","author":"Raz","year":"1997","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2016.11.019_b0090","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm300303e","article-title":"Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization","volume":"55","author":"Shibata","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0095","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/jm060295c","article-title":"DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity","volume":"49","author":"Dardonville","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2016.11.019_b0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"Hirumi","year":"1989","journal-title":"J Parasitol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089616311828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089616311828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:47:16Z","timestamp":1760834836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089616311828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0968089616311828"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2016.11.019","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2016.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}